
OncoLink reporters provide in-depth coverage of scientific presentations from the 45th Annual ASCO Meeting.
|
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214
Presenter: Elizabeth M. Gore, MDPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground Central nervous system (CNS) failure rates are high in patients with locally advanced non-small cell lung cancer. ... |
|
|
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-?2a (IFN) in metastatic renal cell carcinoma (mRCC)
Presenter: B.J. Escudier, et al.Presenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground Renal cell carcinoma (RCC) is diagnosed in more than 120,000 patients in the United States and Europe every... |
|
|
First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005)
Presenter: Christopher NuttingPresenter's Affiliation: On behalf of the PARSPORT Trial Management Group, Cancer Research UKType of Session: ScientificBackground Randomized trials have resulted in relatively good cure rates with combination... |
|
|
Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study
Presenter: Pascal Jean-Pierre, PhD, MPHPresenter's Affiliation: University of Rochester Medical CenterType of Session: ScientificBackground A large number of cancer survivors, ranging from 17-75% in various studies, report difficulties with... |
|
|
Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
Presenter: M.L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, Y. DangPresenter's Affiliation: University of Washington, Seattle, WA; Breastlink, Los Angeles, CAType of Session: ScientificBackground HER2/neu... |
|
|
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
Presenter: N. J. RobertPresenter's Affiliation: US Oncology GroupType of Session: ScientificBackground Bevacizumab (B) is a humanized monoclonal antibody which inhibits VEGF, a known central mediator of angiogenesis. Two previous large... |
|
|
Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01
Presenter: Hiroko Kunitake, MDPresenter's Affiliation: David Geffen School of Medicine at UCLAType of Session: ScientificBackground Over 11 million cancer survivors currently reside in the United States, and this number is estimated to continue to... |
|
|
Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy
Presenter: M.M. O'BrienPresenter's Affiliation: Standford UniversityType of Session: ScientificBackground There has been a steady improvement in the survival rates of pediatric patients with Hodgkin's disease as more effective treatment and... |
|
|
Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls
Presenter: Cecilie E. KiserudPresenter's Affiliation: The Norwegian Radium Hospital, Oslo, NorwayType of Session: ScientificBackground As improved cancer screening and treatments continue to result in higher rates of cancer survival, issues of... |
|
|
Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
Presenter: Paul Nathan, MD, MScPresenter's Affiliation: The Hospital for Sick Children, Toronto, CanadaType of Session: ScientificBackground Series of clinical trials in pediatric oncology, examining outcomes in multiple disease sites, have... |
|
|
Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)
Presenter: M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green, F. Shepherd.Presenter's Affiliation: London Regional Cancer Program, London, ON, CanadaType of Session: ScientificBackground ... |